MAIA Biotechnology Touts Positive Safety Data From Its Potential Lung Cancer Candidate

MAIA Biotechnology Inc MAIA released topline data from the completed Part A safety lead-in of its THIO-101 Phase 2 go-to-market trial in advanced Non-Small Cell Lung Cancer (NSCLC) and has commenced recruitment in Part B randomized efficacy/dose selection.
Topline data from Part A demonstrated that MAIA's telomere-targeting agent, THIO, administered sequentially with Regeneron Pharmaceuticals Inc's REGN Libtayo (cemiplimab), was generally well-tolerated.
No dose-limiting toxicities (DLTs) or significant treatment-related adverse events were observed.
Part A was designed to assess the safety and tolerability of the highest dose of 360 mg/cycle in six patients.
Mild toxicities, such as grade 1 fatigue and muscle pain, were reported, as well as only one occurrence of grade 3 nausea, but no grade 4 adverse events were reported.
Part B of the study will allow the randomization of patients to three THIO dose levels, including 60 mg, 180 mg, and 360 mg, followed by cemiplimab treatment every three weeks.
The objective of Part B is to determine the most efficacious and safe dose, which will guide Part C of the trial.
Price Action: MAIA shares are up 0.35% at $3.62 on the last check Tuesday.